Although Cervarix looks to be a hit, Merck’s Gardasil launched in 2006 will have had almost a year and a half to gain market share before the new competitor arises. At that point, Gardasil will have been a “tried and true” product, making entry more difficult for Cevarix.
GlaxoSmithKline will lose several patents in the next three years, including antidepressants Wellbutrin and Paxil as well as epilepsy and bipolar drug Lamictal